Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy

British Journal of Surgery

Volumn 93, Issue 10, 2006, Pages 1226-1231

  Antonelli, A ^a   Fallahi, P ^a   Rotondi, M ^b   Ferrari, S M ^a   Serio, M ^b   Miccoli, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; THIAMAZOLE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ECHOGRAPHY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYROID FUNCTION; THYROIDECTOMY; TOXIC GOITER; TREATMENT OUTCOME;

ANTITHYROID AGENTS; CASE-CONTROL STUDIES; CHEMOKINES, CXC; FEMALE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 33749589416     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5401     Document Type: Article

References (35)

1. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
2. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R et al. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 1997; 62: 554-562.
3. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
4. Rotondi M, Lazzeri E, Romagnani P, Serio M. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 2003; 26: 177-180.
5. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001; 24: 510-515.
6. Nicoletti F, Gonget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45: 1107-1110.
7. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A et al. Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of patients with recent onset Graves' disease. Am J Pathol 2002; 161: 195-206.
8. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89: 5496-5499.
9. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005; 152: 171-177.
10. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001; 86: 5008-5016.
11. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol 2003; 59: 207-213.
12. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostaticactivity. J Clin Invest 2001; 107: 53-63.
13. Ashhab Y, Dominguez O, Sospedra M, Roura-Mir C, Lucas-Martin A, Pujol-Borrell R. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. J Clin Endocrinol Metab 1999; 84: 2873-2882.
14. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S et al. Anti-CD 38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001; 126: 426-431.
15. Berti P, Materazzi G, Galleri D, Donatini G, Minuto M, Miccoli P. Video-assisted thyroidectomy for Graves' disease: report of a preliminary experience. Surg Endosc 2004; 18: 1208-1210.
16. Antonelli A, Ferri C, Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 1999; 281: 1588 (Letter).
17. Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 2003; 13: 479-484.
18. 131I therapy. Nucl Med Commun 1998; 19: 341-346.
19. Vitti P. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease. Eur J Endocr 2000; 142: 22-24.
20. Antonelli A, Miccoli P, Ferdeghini M, Di Coscio G, Alberti B, Iacconi P et al. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995; 5: 25-28.
21. Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A et al. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest 1995; 18: 857-861.
22. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996; 81: 2976-2979.
23. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000; 143: 197-202.
24. Miyauchi S, Matsuura B, Onji M. Increased levels of serum interleukin-18 in Graves' disease. Thyroid 2000; 10: 815-819.
25. Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995; 132: 668-672.
26. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs I et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 1997; 82: 78-81.
27. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999; 84: 435-439.
28. Watson PF, Pickerill AP, Davies R, Weetman AP. Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 1994; 79: 355-360.
29. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Crespillo-Gomez C, Berg J. Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease. Horm Metab Res 2003; 35: 427-433.
30. Diez JJ, Hernanz A, Medina S, Bayon C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol 2002; 57: 515-521.
31. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995; 25: 654-658.
32. Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311: 1353-1362.
33. Weetman AP, McGregor AM, Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol 1984; 21: 163-172.
34. Weetman AP, Tandon N, Morgan BP. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992; 340: 633-636.
35. Senturk T, Kozaci LD, Kok F, Kadikoylu G, Bolaman Z. Proinflammatory cytokine levels in hyperthyroidism. Clin Invest Med 2003; 26: 58-63.